NanoViricides, Inc. (OTC BB: NNVC) has retained Australian Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide(TM), the Company’s broad-spectrum anti-influenza drug. Australian Biologics will also facilitate clinical trial site(s) selection and development of the clinical trials agreements. The Company believes that it will have the capability for producing drugs suitable for human clinical trials when renovation of the new facility in Shelton is completed. In parallel, the Company continues to pursue appropriate human clinical study pathways for its highly effective anti-influenza drug candidate, NV-INF-1, in the FluCide™ program. The Company has engaged Australian Biologics to study and develop a roadmap for conducting certain Phase 1 and Phase 2 human clinical studies in Australia. NV-INF-1 has been shown to be highly effective in controlling influenza viral infection in lethal infection mouse model. Animals survived for full duration of the study (21 days) when treated with NV-INF-1 on alternate days. In contrast, oseltamivir-treated animals (40mg/kg given every day) survived for only 8 days. Untreated animals survive only 5 days in this highly lethal influenza infection model. The Company has previously reported that depending upon the treatment protocol, NV-INF-1 has shown viral load reduction of 1.3 logs to 3 logs in these various studies. In contrast, oseltamivir (Tamiflu(R)) treatment in the same studies has resulted in viral load reductions of only about 0.2 logs to 0.8 logs.
http://www.nanoviricides.com
CEA Liten (France), Innovation Lab (Germany) and the University of Sheffield (UK) have each independently selected and purchased Aerosol Jet deposition systems. The systems are used for the development of next-generation technologies for electronic sensors and displays, 3D conformal electronic devices, fuel cells and solar cells, and other emerging printed electronics applications. With the addition of these marquee industrial labs, the total number of Optomec users in Europe now exceeds 40 leading institutions and corporations. Innovation Lab GmbH (iL) is an application-oriented organization for research and knowledge transfer in science and business. Innovation Lab is located in the Rhine-Neckar metropolitan region, and is supported by the Universities of Heidelberg and Mannheim, and by the companies BASF SE, Merck KGaA, Freudenberg & Co., Heidelberger Druckmaschinen AG, Roche Diagnostics GmbH and SAP AG.
http://www.optomec.com/
P2i has received the title of "Outstanding New Product/Service" for its innovative development of the Aridion(TM) liquid repellent nano-coating tech- nology for high volume manufacturing.
http://www.p2i.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105